IQVIA™ Real-World Insights Bibliography

THE COST OF STIGMA ASSOCIATED WITH HIV- A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA
Author(s): Filemban S1, Elrashied S1, Assiri A1, Hakawi A1, Snehanshu S2, Mansour E3, Vemer P4, Awad N5
Affiliations(s): 1Ministry of Health, Riyadh, Saudi Arabia, 2Gilead Sciences Middle East, Dubai Health Care City, United Arab Emirates, 3Gilead, Dubai, United Arab Emirates, 4Groningen University, Groningen, Netherlands, 5IQVIA, Dubai, United Arab Emirates
Publication(s):  2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Document Type(s): Poster,
Countries: Saudi Arabia,
Click here for the abstract
C:
Y:
HIV AIDS,
2019
  L:
A:
English
Predictive analytics, Quality of life,
  Add to report
 
 
Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States.
Author(s): Dekoven M, Makin C, Slaff S, Marcus M, Maiese EM.
Affiliations(s): IMS Health, Fairfax, VA, USA. Yoh Services LLC, Philadelphia, PA, USA. Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA emaiese@gmail.com
Publication(s):  J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):66-76
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
HIV AIDS,
2016
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Author(s): Moeremans K1, Hemmett L2, Hjelmgren J3, Allegri G4, Smets E5
Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Tibotec, Buckinghamshire, UK 3 Janssen-Cilag AB, Stockholm, Sweden 4 Janssen-Cilag SpA, Cologno Monzese, Italy 5 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium
Publication(s):  Pharmacoeconomics, 2010, 28 (Suppl 1): 147-167
Document Type(s): Article,
Countries: Belgium, Italy, Sweden, UK,
C:
Y:
HIV AIDS,
2010
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Cost-effectiveness of etravirine in Sweden in treatment-experienced HIV-1-infected adults with evidence of NNRTI resistance and ? 3 PI mutations.
Author(s): Moeremans K1, Hjelmgren J2, Martin S3
Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Janssen-Cilag, Birkeöd, Denmark 3 J&J, Mechelen, Belgium
Publication(s):  12th European Aids Conference, 2009, November 11-14, Cologne, Germany
ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France
Document Type(s): Poster,
Countries: Sweden,
C:
Y:
HIV AIDS,
2009
  L:
A:
English
Cost utility,
  Add to report
 
 
Cost effectiveness of darunavir/ritonavir 600/100mg BID in treatment-experienced, LPV/R-naïve, PI-resistent, HIV-infected adults in the United Kingdom, Belgium, Italy and Sweden.
Author(s): Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E
Affiliations(s): 
Publication(s):  ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece
Document Type(s): Oral presentation,
Countries: Belgium, Italy, Sweden, UK,
C:
Y:
HIV AIDS,
2008
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Cost-Effectiveness Analysis of Enfuvirtide (ENF) Added to an Optimized Therapy vs an Optimized Therapy Alone in Patients With HIV/AIDS.
Author(s): Badia X, Lizan L, Magaz S, Alvarez C, Green J, Serrano D.
Affiliations(s): 
Publication(s):  HIV Clinical Trials 2007;8(4):235-45
Document Type(s): Manuscript in preparation,
Countries: Spain,
Click here for the abstract
C:
Y:
HIV AIDS,
2007
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Experienced HIV/AIDS patients in different European healthcare settings
Author(s): Moeremans Karen, Annemans Lieven,; Smets Erik, Wyffels Veronique, Lothgren Mickael , Allegri Gabriele
Affiliations(s): 
Publication(s):  ISPOR 2007 10th Annual European Congress
Document Type(s): 
Countries: Europe,
C:
Y:
HIV AIDS,
2007
  L:
A:
English
  Add to report
 
 
Cost of care for HIV/AIDS in Belgium according to disease stage.
Author(s): Caekelbergh K1, Moeremans K1, Annemans L2, De Roo A3, Clumeck N4, Van Wijngaerden E5, Vandercam B6, Moutschen M7, Smets E8
Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Ghent University, Ghent, Belgium 3 Institute for Tropical Medicine, Antwerp, Belgium 4 St. Pierre University Hospital, Brussels, Belgium 5 University Hospital Leuven, Belgium 6 University Hospital St. Luc, Brussels, Belgium 7 University Hospital Sart Tilman, Liège, Belgium 8 Johnson & Johnson Pharmaceutical Services, Mechelen, Belgium
Publication(s):  11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain
Document Type(s): Oral presentation,
Countries: Belgium,
C:
Y:
HIV AIDS,
2007
  L:
A:
English
Cost of illness,
  Add to report
 
 
Cost-effectiveness of DRV/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings.
Author(s): Moeremans K, Annemans L, Smets E, Wyffels V, Wilson B, Lothgren M, Allegri G
Affiliations(s): 
Publication(s):  11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain
Document Type(s): Oral presentation,
Countries: Belgium,
C:
Y:
HIV AIDS,
2007
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Cost-effectiveness of Darunavir/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings.
Author(s): Moeremans K, Annemans L, Smets E, Wyffels V, Lothgren M, Allegri G
Affiliations(s): 
Publication(s):  ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland
Document Type(s): Oral presentation,
Countries: Belgium,
C:
Y:
HIV AIDS,
2007
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
 1 of 2 Next Page Last Page